Epitomics launches 23 novel cancer-related antibodies

Download PDF Copy

Jul 27 2011

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAb®) technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research. The goal of this partnership is to develop novel, high quality reagents for cancer research and make them available to the scientific community.

"We are very excited to see the progress we have made in developing several key antibodies with NCI investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

SOURCE Epitomics, Inc.

Posted in: Medical Science News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

New method reveals how mitochondrial DNA mutations influence cancer growth

Cancer cells found to use ketones as alternate fuel for growth

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

New tool can predict where deadly brain cancer might reappear

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

‘Rogue’ DNA rings identified as drivers of aggressive brain cancer

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Many patients undergoing surgery for early-stage cancer continue or start opioid prescriptions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.